Genprex, Inc. (NasdaqCM: GNPX)
Health Care · Biotechnology · US
$1.81
-8.59% today · -99.1% 1Y
Genprex, Inc. (NasdaqCM: GNPX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.48M and employs 13 people.
Over the last twelve months the share price has lost 99.1%, trading between 2.03 and 285.34.
Tweenvest scores Genprex, Inc. across four factors: quality 35/100, value 10/100. Its strongest factor is quality.
GNPX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.48M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -71.69
- Dividend yield
- —
- Beta (5Y)
- -0.97
- 52-week high
- $285.34
- 52-week low
- $2.03
- Avg volume (3M)
- —
- Shares outstanding
- 819.71K
- Employees
- 13
- Next earnings
- —
About Genprex, Inc.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.
- ISIN
- US3724464017
- Founded
- 2009
- Listed since
- Mar 29, 2018
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cynata Therapeutics LimitedASX: CYP | $1.86M | AU$0.01 | -21.43% |
| Neural Therapeutics Inc.CNSX: NURL | $1.79M | CA$0.02 | -25.00% |
| Respiratorius AB (publ)XSAT: RESP | $1.72M | Skr— | — |
| Curis, Inc.NasdaqCM: CRIS | $1.59M | $0.39 | -4.59% |
| BioSenic S.A.ENXTBR: BIOS | $1.47M | €0.00 | -9.09% |
| Hexima LimitedASX: HXL | $1.44M | AU$— | — |
| NKGen Biotech, Inc.OTCPK: NKGN | $1.44M | $0.01 | -0.90% |
| Lakewood-Amedex Biotherapeutics, Inc.NasdaqCM: LABT | $1.37M | $0.58 | -25.85% |
Figures last refreshed Oct 18, 2026.